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The role of CpG island methylation in normal development and cell differentiation is of keen interest, but remains
poorly understood. We performed comprehensive DNA methylation profiling of promoter regions in normal peripheral
blood by methylated CpG island amplification in combination with microarrays. This technique allowed us to
simultaneously determine the methylation status of 6,177 genes, 92% of which include dense CpG islands. Among
these 5,549 autosomal genes with dense CpG island promoters, we have identified 4.0% genes that are nearly
completely methylated in normal blood, providing another exception to the general rule that CpG island methylation
in normal tissue is limited to X inactivation and imprinted genes. We examined seven genes in detail, including
ANKRD30A, FLJ40201, INSL6, SOHLH2, FTMT, C12orf12, and DPPA5. Dense promoter CpG island methylation and gene
silencing were found in normal tissues studied except testis and sperm. In both tissues, bisulfite cloning and
sequencing identified cells carrying unmethylated alleles. Interestingly, hypomethylation of several genes was
associated with gene activation in cancer. Furthermore, reactivation of silenced genes could be induced after
treatment with a DNA demethylating agent or in a cell line lacking DNMT1 and/or DNMT3b. Sequence analysis
identified five motifs significantly enriched in this class of genes, suggesting that cis-regulatory elements may facilitate
preferential methylation at these promoter CpG islands. We have identified a group of non-X–linked bona fide
promoter CpG islands that are densely methylated in normal somatic tissues, escape methylation in germline cells, and
for which DNA methylation is a primary mechanism of tissue-specific gene silencing.
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Introduction
CpG islands (CGIs) are discrete CpG-rich regions present
in the promoters of 50%–70% of human genes [1]. DNA
methylation within CGIs is associated with mitotically stable
gene silencing (an epigenetic process). Such CGI methylation
is involved physiologically in genomic imprinting [2] and X
inactivation [3] and pathologically in developmental diseases
[4] and cancer [5]. The role of CGI methylation in normal
development, stem cell physiology, and differentiation,
however, remains poorly understood [6].
Inhibition of DNA methylation can transform ﬁbroblasts
into muscle cells and other differentiated cells, suggesting
that gene methylation regulates the process of differentiation
[7]. However, support for this idea was dampened when CGIs
were generally found to be unmethylated regardless of tissue-
speciﬁc expression [8], and tissue-speciﬁc genes thought to be
regulated by methylation were unaffected by demethylation
in vivo [9]. It is now widely held that CGIs associated with
both housekeeping and tissue-speciﬁc genes are unmethy-
lated at any developmental stage, except when associated with
certain imprinted genes and genes subject to X inactivation.
While most CGIs are unmethylated in normal tissues, there
is increasing evidence that a few CGIs are in fact methylated
in normal tissues independent of imprinting and X inactiva-
tion, and may play a role in the differentiation process
through programmed expression of tissue-speciﬁc genes. At
several genes, CpG island methylation has been correlated
with transcriptional inactivation in normal cells. Most such
correlations, however, involve intragenic CGIs rather than
promoter CGIs [10,11]. A few promoter CGIs were found at
which methylation correlates with transcription [12,13], but
those contain a low density of CpG sites. For example, a
recent study proﬁling genome-wide DNA methylation in
three human chromosomes (Chr 6, 20, and 22) demonstrated
that a small subset of promoter-region CGIs are methylated
in various normal tissues, but all have a CpG density less than
Editor: Bas van Steensel, Netherlands Cancer Institute, The Netherlands
Received February 6, 2007; Accepted September 7, 2007; Published October 26,
2007
A previous version of this article appeared as an Early Online Release on September
10, 2007 (doi:10.1371/journal.pgen.0030181.eor).
This is an open-access article distributed under the terms of the Creative Commons
Public Domain declaration which stipulates that, once placed in the public domain,
this work may be freely reproduced, distributed, transmitted, modified, built upon,
or otherwise used by anyone for any lawful purpose.
Abbreviations: CGI, CpG island; DAC, 5-aza-29-deoxycytidine; GO, gene ontology;
MAST, motif alignment and search tool; MCA, methylated CpG island amplification;
MCAM, methylated CpG island amplification in combination with microarray;
MEME, multiple EM for motif mlicitation; PBL, peripheral blood leukocyte; TSA,
trichostatin A
* To whom correspondence should be addressed. E-mail: lshen@mdanderson.org
PLoS Genetics | www.plosgenetics.org October 2007 | Volume 3 | Issue 10 | e181 202310% [14]. That study also identiﬁed a considerable number of
tissue-differentially methylated regions in CGIs, but these
were preferentially located several kilobases away from the
transcription start site of associated genes. Thus, the dogma
that promoter-associated dense CGIs are unmethylated in
normal tissues persists. A full appreciation of the role of CGI
methylation in normal development awaits a careful high-
throughput analysis of the process.
In this study, we compared differential methylation in
normal tissues by genome-wide CGI methylation proﬁling
and discovered non-X–linked bona ﬁde promoter CGIs that
are densely methylated in normal somatic tissues and escape
methylation in germline cells. CGI hypermethylation at these
gene promoters appears to be a primary mechanism of tissue-
speciﬁc gene silencing.
Results
Genome-Wide Methylation Analysis by Methylated CpG
Island Amplification in Combination with Microarray
We performed a comprehensive DNA methylation proﬁl-
ing of gene promoter regions in normal peripheral blood by
methylated CpG island ampliﬁcation (MCA) in combination
with microarrays (MCAM). This procedure is described in
Materials and Methods and outlined in Figure S1. Essentially,
MCAM involves two steps. First, MCA [15] is used to enrich
for methylated fragments. Second, labeling and cohybridiza-
tion of MCA products to arrays enables comparison of locus-
speciﬁc methylation between samples. We used promoter
microarrays that contained 45- to 60-mer oligonucleotide
probes covering from  1.0 kb to þ0.3 kb relative to the
transcription start sites of 18,000 human genes. Bioinformatic
analysis predicted that 22,294 probes corresponding to 6,177
unique genes on the array would be informative when using
SmaI/XmaI enzymes to generate methylated fragments up to
1 kb in size (see Materials and Methods). We also annotated all
the SmaI/XmaI sites for CGIs and repetitive sequences.
Among these informative genes on the arrays, gene pro-
moters associated with dense-CGIs, sparse-CGIs and non-
CGIs were 5,692 (92%), 318 (5%), and 167 (3%) respectively.
In an initial validation of MCAM, we compared in vitro
fully methylated genomic DNA with DNA isolated from
normal peripheral blood leukocytes (PBLs). As expected, the
signal intensity of Cy5 (fully methylated) was high at most
(87.1 %) informative probes (Figure S2A and S2B). The 12.9%
of probes that did not show high signal in the positive control
could be attributed to a PCR bias caused by the increased
complexity of performing MCA on an artiﬁcially hyper-
methylated genome. Alternatively, nonsigniﬁcant signal could
occur at probes with poor discriminative ability. Therefore,
we estimated that MCAM technique has a false negative rate
of less than 12.9%.
We compared the signal intensity of ﬂuorescent probes
between two independent hybridizations using MCA prod-
ucts processed at different times from the same normal PBL
DNA sample, and found that the correlation between the two
duplicates was 0.94, indicating that the technique is highly
reproducible (Figure S2C).
In the cohybidization of MCA product from fully methy-
lated DNA and normal PBL DNA, we observed probes
showing high signal intensity in both channels (Figure S2B),
suggesting genes hypermethylated in normal PBLs. Surpris-
ingly, a subset of genes showed signiﬁcantly higher signal in
PBLs than in fully methylated DNA. This is possible because
the relatively low number of hypermethylated regions in
PBLs will amplify with higher efﬁciency compared with fully
methylated DNA in the MCA reaction. We randomly selected
38 genes showing such high signal intensity in PBLs and
analyzed them by a quantitative bisulﬁte pyrosequencing
method. Of these, 17 showed dense (.70%) methylation in
normal PBLs, six showed moderate (15% to 70%) methyl-
ation, and 15 showed low (,15%) methylation (Figure S3).
Genes that were densely methylated in PBLs showed the
highest signal intensity ratio (PBLs versus fully methylated
DNA), with median ratio of 2.2; the median ratio in genes
with moderate and low methylation was 1.5 and 0.7,
respectively. Hence, a relatively high signal intensity (.3-
fold of background) combined with a signal ratio   1.5
relative to in vitro-methylated DNA appears to identify
hypermethylated loci in PBLs with 93% speciﬁcity and 74%
sensitivity.
Promoter Methylation in Normal Tissues
Using these criteria, we identiﬁed 455 genes methylated in
normal PBLs (Table S1). 258 of these gene promoters were
associated with dense-CGIs, 129 were associated with sparse-
CGIs, and 68 were associated with non-CGIs. Thus, we
estimate that 4.5% (258/5,692) of promoter-associated
dense-CGIs are methylated in normal PBLs, while 40.5%
(129/318) and 40.7% (68/167) of sparse-CGI and non-CGI
promoters show such methylation. Methylated promoter
CGIs were distributed throughout the genome (Figure S4).
Interestingly, most of the identiﬁed CGIs were autosomal; in
these, the frequency of methylation was 4.0% (223/5,549) for
dense-CGI promoters, 39.4% (121/307) for sparse-CGI pro-
moters and 40.9% (65/159) for non-CGI promoters. Except
for MEST, none of these was associated with known imprinted
genes. Together, these data modify the notion that CGI
methylation is limited to X chromosome and imprinted genes
in normal tissues. Our results also indicate that both non-CGI
and sparse-CGI promoters are frequently methylated in
normal somatic tissues.
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Author Summary
About half of all human genes contain a CpG-rich region called a
‘‘CpG island’’ in the 59 area, often encompassing the promoter and
transcription start site of the associated gene. DNA methylation was
initially suggested to control tissue-specific gene expression in
mammalian cells, but most promoter region CpG islands were found
to be unmethylated regardless of tissue specificity of expression. In
this study, we discovered an exceptional subset of autosomal genes
associated with dense promoter CpG islands that is methylated in
normal tissues. We observed tissue-specific gene silencing corre-
lated with hypermethylation in this class of genes, and provided
evidence for a direct role of methylation in maintaining the silencing
state. Furthermore, we identified five sequence motifs significantly
enriched in this class of genes, suggesting the influence of cis-
regulatory elements on the establishment and/or stability of DNA
methylation. Together, these results provide important new insights
into the role of CpG island methylation in normal development and
differentiation.A Class of Genes with Dense Promoter CGI Methylation
and Silencing in Normal Tissues
Since most CGIs previously known to be methylated in
normal tissues are located in intragenic regions or promoters
of intermediate CpG density, we were surprised to ﬁnd this
exceptional class of autosomal gene promoters associated
with dense-CGIs (4.0% of all such CGIs analyzed) that are
methylated in normal PBLs. We used bisulﬁte pyrosequencing
to measure DNA methylation quantitatively at such promoter
CGIs for 17 genes and conﬁrmed the methylation level of
each gene ranged from 68% to 93% in normal PBLs (Table 1).
We also measured the methylation of all these genes in two
cancer cell lines (the leukemia cell line K562 and the colon
cancer cell line RKO) and normal testis. Relative to PBLs, we
observed promoter hypomethylation in the cancer cells and
testis. This was most striking in K562, where hypomethylation
was found in all 17 genes.
As shown in Table 2, analysis of chromosomal location,
CpG density, and GC content of these genes revealed that all
have typical CGIs in their promoters, with high CpG densities
Table 1. Bisulfite Pyrosequencing Results of Genes Methylated in PBLs by MCAM
Characteristics of Each Gene MCAM Results Bisulfite Pyrosequencing
Gene
Name
Chr Accession No. Fragment
Length (bp)
Enzyme Sites Cy3
Signal (PBL)
Ratio
(PBL /SssI)
CpGs
tested
Samples
In CGI In repeat PBL K562 RKO Testis
Start End Start End
FLJ40201 1 NM_152607 834 Y N N N 26899.9 1.9 5 84 15 95 34
KCNE4 2 NM_080671 732 N Y N N 134539.8 3.3 10 90 81 78 40
FTMT 5 NM_177478 940 N Y Y N 18893.7 3.1 6 88 26 91 65
ME1 6 NM_002395 256 Y N N N 335191.2 1.8 5 89 2 92 56
DPPA5 6 NM_001025290 293 Y Y N N 14284.6 1.4 5 85 46 94 43
MEST 7 NM_177524 68 Y Y N N 20813.9 4.1 6 86 57 87 71
OPLAH 8 NM_017570 340 N Y N N 279457.9 2.7 12 88 23 23 52
INSL6 9 NM_007179 835 Y Y N Y 144513.1 4.9 17 89 62 91 45
ACTL7B 9 NM_006686 1,186 Y N N N 105240.5 1.0 6 87 11 93 55
ANKRD30A 10 NM_052997 1,051 Y Y Y N 20233.6 2.4 10 90 45 91 47
C12orf12 12 NM_152638 438 Y Y N N 284317.7 2.9 18 80 34 71 59
RNF113B 13 NM_178861 359 Y Y N Y 145160.3 2.2 6 93 34 92 89
SOHLH2 13 NM_017826 336 Y Y N N 283227.8 3.3 7 91 7 53 62
SHANK1 19 NM_016148 192 N N N N 241668.5 1.6 5 88 57 86 89
ZNF541 19 AL833862 319 N N N N 384305.0 1.8 8 79 69 75 75
C19orf24 19 AK128423 484 Y Y N N 123270.1 1.1 5 77 0 3 14
CTL2 19 NM_020428 808 Y N N Y 101965.4 2.1 4 68 53 32 16
doi:10.1371/journal.pgen.0030181.t001
Table 2. Characteristics of CGI Promoters for Genes Densely Methylated in PBL
Gene
Name
Chromosome
Band
Functions 200-bp Window 500-bp Window
CGI
Size
%o f
CpG
%GC
content
Obs/Exp
CpG
CGI
Size
%o f
CpG
%G C
content
Obs/Exp
CpG
FLJ40201 1p32.3 Hypothetical protein LOC163747 307 21.5 73.3 0.80 535 13.5 64.5 0.65
KCNE4 2q36.1 Potassium voltage-gated channel, Isk-related 461 14.3 64.0 0.70 544 12.9 62.9 0.65
FTMT 5q23.1 Mitochondrial ferritin 737 19.3 68.0 0.85 1,269 12.6 59.2 0.73
ME1 6q14.2 Cytosolic malic enzyme 1 586 15.0 59.4 0.91 1,093 14.3 66.1 0.67
DPPA5 6q13 Developmental pluripotency associated 5 952 13.2 59.5 0.75 951 13.0 63.4 0.65
MEST 7q32.3 Mesoderm specific transcript isoform b 2,372 14.9 60.2 0.83 2,799 14.9 59.7 0.80
OPLAH 8q24.3 5-oxoprolinase (ATP-hydrolyzing) 1,278 18.3 71.6 0.72 1,128 18.3 73.9 0.67
INSL6 9p24.1 Insulin-like 6 precursor 447 18.3 62.9 0.93 978 11.5 55.0 0.76
ACTL7B 9q31.3 Actin-like 7B 824 16.3 64.3 0.79 1,112 14.2 65.1 0.67
ANKRD30A 10p11.21 Ankyrin repeat domain 30A 624 16.3 68.6 0.71 850 13.6 65.2 0.65
C12orf12 12q21.33 Chromosome 12 open reading frame 12 292 20.5 69.5 0.85 549 12.8 62.7 0.65
RNF113B 13q32.2 Ring finger protein 113B 1,002 15.4 63.5 0.76 1,506 12.0 59.3 0.68
SOHLH2 13q13.3 Germ cell-specific hHLH transcription factor 624 15.7 69.6 0.65 523 15.7 69.4 0.65
SHANK1 19q13.33 SH3 and multiple ankyrin repeat domain 1 244 18.9 72.1 0.73 No No No No
ZNF541 19q13.32 Zinc finger protein 541 1,366 15.7 70.4 0.65 1,120 16.4 70.1 0.67
C19orf24 19p13.3 Hypothetical protein LOC55009 1,889 21.8 68.6 0.93 2,011 21.0 71.1 0.83
CTL2 19q13.2 Choline transporter like protein 2 397 23.2 76.1 0.81 751 15.7 69.5 0.65
The characteristics of CGIs were calculated in consecutive nonoverlapping 200-bp and 500-bp windows stating on one end of a contig and progressing to the other. The percentage of
CpG is the ratio of CpG nucleotide bases (twice the CpG count) to the length. CGIs of all genes are located in the promoter, except KCNE4, which may contain it in an alternative promoter.
doi:10.1371/journal.pgen.0030181.t002
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Normally Methylated CpG Island Promotersranging from 13.2% to 23.2%, and all are located on
autosomes with no apparent association with common
repetitive sequences or pseudogenes. To determine if
methylation affects only a few CpG sites or all CpG sites
across the island, we carried out bisulﬁte cloning and
sequencing for seven of these genes, ANKRD30A, FLJ40201,
INSL6, SOHLH2, FTMT, DPPA5, and C12orf12. All genes were
selected on the basis of methylation levels greater than 80%
in PBLs by bisulﬁte pyrosequencing for limited CpG sites.
Bisulﬁte cloning and sequencing provided allele speciﬁc
methylation data on a larger number of CpG sites, and again
showed extensive methylation at all CpG sites within CGIs in
normal PBLs (Figure 1, left), but little or no methylation in
K562 (Figure 1, right).
To assess the extent of tissue and cell-type speciﬁc DNA
methylation at these CGI promoters, we used quantitative
bisulﬁte pyrosequencing to analyze 33 normal samples
derived from ten human tissues: blood, colon, liver, breast,
brain, ﬁbroblast, prostate, skeletal muscle, testis and sperm.
Dense methylation at these CpG island promoters was found
in all tissues except sperm and testis (Figure 2A). Bisulﬁte
cloning and sequencing of sperm DNA identiﬁed cells
carrying completely unmethylated alleles (Figure 2B). Among
the sequences obtained from testis, some alleles were almost
completely unmethylated, whereas others were heavily
methylated (Figure 2C). As adult testicular tissue contains a
mixture of germ line and somatic cells, these results suggest
that these unmethylated alleles are derived from germ line
cells. We hypothesized that the methylation patterns we
observed could predict tissue-speciﬁc silencing. To test this,
we examined the expression of all genes except two intronless
genes (FTMT and C12orf12) in a cDNA panel from 20 normal
tissues. Consistent with the DNA methylation status, all ﬁve
genes analyzed were strongly expressed in testis (Figure 3).
Except SOHLH2, expression of four genes (strong expression
of three and weak expression of one) was also detected in
sperm. However, expression of SOHLH2 has been reported in
oocytes [16]. In contrast, most normal somatic tissues showed
no or weak expression of these genes with the exceptions of
INSL6 and SOHLH2; INSL6 was expressed in kidney, placenta,
prostate, and salivary gland, and SOHLH2 was expressed in
placenta and prostate. Due to limited tissue availability, we
were unable to examine methylation and expression in all
tissues; however, we analyzed methylation of INSL6 and
SOHLH2 in placenta and found promoter hypomethylation
for both genes (17.6% for INSL6 and 20.9% for SOHLH2). We
conclude that these genes belong to a unique class of
promoter CGI associated genes that are methylated and
silenced in a tissue-speciﬁc manner.
Gene Ontology and Expression analysis
To explore potential shared functionality of this class of
methylated genes with dense-CGI promoters, we used GOstat
gene ontology analysis [17,18] and Benjamini-Hochberg
multiple testing correction to identify gene ontology catego-
ries that are signiﬁcantly over-represented. We found most of
these genes to be involved in intracellular membrane bound
organelle functions (34.1%, p ¼ 0.05), followed by metal ion
binding (29.4%, p¼0.0006) and signalosome functions (1.6%,
p ¼ 0.04) (Figure 4A). Using published microarray expression
databases and applying Z-scores to assign equal weight to
each gene, we compared the expression levels of 127 genes
among 66 different normal tissues and/or cell-types (see
Materials and Methods for details). As shown in Figure 4B,
expression level analyzed by Z-score for all genes was highest
in testis, and high in testis-derived cells. Consistent with our
methylation data, expression level was greatly decreased in
whole blood, as well as various subtypes of blood cells. Indeed,
69% of genes analyzed showed negative Z-scores in whole
blood relative to other tissue types, which is highly signiﬁcant
(p , 2310
 7, assuming a binomial distribution). These results
again suggest that methylation at these promoter CGIs is
associated with tissue-speciﬁc gene silencing.
DNA Sequence Analysis
To identify sequence characteristics that could differ-
entiate this class of methylated dense-CGI promoters from
the bulk of unmethylated dense-CGI promoters, we ﬁrst
compared CGI size, GC content, and the ratio of observed to
expected CpG frequency for these two group of genes
identiﬁed by MCAM (see Materials and Methods for details).
There was no signiﬁcant difference in CGI length or the ratio
of Obs/Exp CpG between the two groups (the average CGI
length was 1,157 bp in methylated CGIs versus 1,248 bp in
unmethylated CGIs, and the ratio of Obs/Exp CpG was 0.88 in
methylated CGIs versus 0.88 in unmethylated CGIs). The
methylated CGIs had a slightly higher GC content compared
to unmethylated CGIs (66.5 versus 65.6, respectively, p¼0.02).
Next we used a weight matrix ﬁnding algorithm (MEME)
[19] and motif alignment and search tool (MAST) [20] to
identify sequence motifs that predict methylation patterns.
We generated two sets of sequences, one containing 138
sequences (2 kb window) ﬂanking the center of CGIs at
methylated genes, and the other containing 2,125 sequences
ﬂanking the center of CGIs at unmethylated genes. MEME was
used to identify the top 20 signiﬁcant motifs in each set of
sequences (methylated or unmethylated group), and then
MAST was used to identify motifs that occur differentially
between the methylated and unmethylated groups. Of the top
20 motifs enriched in the methylated group, ﬁve showed a
signiﬁcantly higher occurrence in the methylated relative to
the unmethylated group (p , 0.02 by Fisher exact tests)
(Figure 5). In contrast, the top 20 motifs identiﬁed in the
unmethylated group were present at the same frequency in
both groups. Using the TRANSFAC database search, none of
these ﬁve discriminating motifs was associated with any
known transcription factor binding site. Interestingly, how-
Figure 1. Bisulfite Sequencing of Seven CGI Promoters in PBL and K562
For each gene, a diagram of the CGI promoter is shown on the left. Each vertical line represents a single CpG site. The transcription start site, location
of exon 1 and restriction enzyme sites are shown on the top. Thick bars indicate the location of regions analyzed by bisulfite-sequencing. Bisulfite
sequencing results are shown on the right. Each row represents an individual cloned allele. Circles represent CpG sites and their spacing accurately
reflects the CpG density of the region. Black circles, methylated CpG site; white circles, unmethylated CpG site. Dense methylation at the CGI promoters
was found in PBLs. In contrast, promoter hypomethylation for all genes was found in K562.
doi:10.1371/journal.pgen.0030181.g001
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gous to Alu sequences (Figure 5).
Promoter CGI Hypomethylation and Aberrant Expression
in Cancer
Global genomic hypomethylation and aberrant promoter
hypermethylation are epigenetic hallmarks of tumorigenesis
[21–23]. We therefore wished to determine if the genes we
identiﬁed have aberrant promoter methylation in tumors.
Methylation analysis of a panel of 61 cancer cell lines from 13
major tumor types including leukemia, melanoma, terato-
carcinoma, bladder, breast, brain, ovarian, colon, liver, lung,
prostate, kidney, and skin revealed a considerable number of
tumors with promoter hypomethylation at the seven pro-
moter CGIs we analyzed. As shown in Figure 6A, the
frequency of promoter hypomethylation (deﬁned as methyl-
ation level less than 70%) was 9.8% (6/61) for ANKRD30A,
9.8% (6/61) for FLJ40201, 8.2% (5/61) for INSL6, 41.0% (25/61)
for SOHLH2, 44.2% (27/61) for FTMT, 49.2% (30/61) for
C12orf12, and 6.6% (4/61) for DPPA5.
Next, we examined gene expression in 12 of these cancer
cell lines, and observed aberrant expression in association
with promoter hypomethylation in several. For example,
hypomethylation of ANKRD30A corresponded with expres-
sion in K562, and relative hypomethylation of SOHLH2
corresponded with its expression in K562, LNCAP, UC13,
and UC3 (Figure 6A and 6B). We also observed a few cases in
which hypomethylation does not correlate with gene activa-
tion, such as FLJ40201 in K562. This could occur if, in
addition to hypomethylation, gene activation requires spe-
ciﬁc transcription factors. Among 12 cancer cell lines for
which both methylation and expression of these ﬁve genes
were assessed (Figures 6B and 7A), in only one case (INSL6 in
LNCAP cells) did we observe both aberrant expression and
promoter hypermethylation. This expression could possibly
originate from a rare subpopulation of hypomethylated cells.
Methylation proﬁles were also assessed in tumor tissue
samples from ten primary colorectal cancer patients and ten
myelodysplastic syndrome patients (Figure 6C). As in the
cancer cell lines, we observed promoter hypomethylation in
the primary tumors; the frequency of hypomethylation was
5% (1/20) for ANKRD30A, 20% (4/20) for FLJ40201, 0% (0/20)
for INSL6, 30% (6/20) for SOHLH2, 20% (4/20) for FTMT, 25%
(5/20) for C12orf12, and 30% (6/20) for DPPA5.
Figure 2. DNA Methylation Analyses in a Panel of Normal Tissues
(A) Methylation profiling in normal tissues by bisulfite-pyrosequencing. Promoter methylation of seven identified genes and global methylation by
LINE1 methylation were examined in normal tissues (top) and primary cultured normal cells (bottom). Number of CpG sites analyzed for each gene is
indicated in the second row. Methylation level is scored into four scales: Filled black boxes, methylation level greater than 75%; filled dark grey boxes,
methylation level from 50% to 75%; filled light grey boxes, methylation level from 25% to 50%, and open boxes, methylation level less than 25%.
(B and C) Bisulfite sequencing in sperm (B) and testis (C) DNA identified cells carrying completely unmethylated alleles in all the genes analyzed.
doi:10.1371/journal.pgen.0030181.g002
Figure 3. Gene Expression by RT-PCR in a Normal Tissue Panel
Tissue types are indicated above the data. The name of each gene amplified is indicated on the left of each column. PCR was performed by using
samples prepared with (RTþ) or without (RT ) reverse transcriptase. GAPDH was amplified to show the integrity of the RNA.
doi:10.1371/journal.pgen.0030181.g003
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Genes
To investigate the role of DNA methylation in transcrip-
tional regulation of these genes, we examined the effects of
treatment with DNA-methyltransferase inhibitor 5-aza-29-
deoxycytidine (DAC) or histone deacetylase inhibitor trichos-
tatin A (TSA) on gene expression in six cancer cell lines and
two primary cultures of normal cells (Figure 7A). In most
cancer cell lines, reactivation of the silenced genes was
observed in response to the treatment with DAC or the
combination of DAC and TSA; in contrast, TSA alone had no
or little effect. We also observed gene reactivation in the
primary cultures of normal cells after DAC and TSA
combined. Relatively weak gene reactivation was observed
in these normal cells after 1 or 5 lM DAC alone for 3 d;
perhaps the result of slower cell division in normal cells, since
DAC causes time- and cell division–dependent demethylation
by trapping DNMT1 [24].
Bisulﬁte pyrosequencing demonstrated that low-dose DAC
(1 lM) alone and the combination of DAC with TSA
signiﬁcantly reduced methylation at all gene promoters
(Figures 7B and S5), whereas TSA alone did not affect
methylation. Interestingly, we observed less hypomethylation
in cells treated with high-dose DAC (5 lM), consistent with
the notion that low-dose DAC speciﬁcally inhibits DNA
methylation, whereas high-dose DAC results in cytotoxicity.
We next analyzed methylation of each gene in a colorectal
cancer cell line (HCT116) after partial knockout of DNMT1,
knockout of DNMT3b or knockout of both enzymes (DKO)
[25,26]. All genes were heavily methylated in parental cells,
and showed dramatic hypomethylation in DKO cells (Figure
8A). For six of the genes (ANKRD30A, FLJ40201, INSL6,
Figure 4. GO Analysis and Tissue-Specific Expression Patterns for Dense-CGI Associated Autosomal Genes Methylated in PBLs
(A) GO analysis of this class of genes. Each bar represents the frequency of significant GO terms.
(B) Gene expression pattern analysis (GNF database) for 127 genes analyzed by Z-score. The y-axis indicates the Z-score sum for all genes in a given
sample. Each bar represents a normal tissue or cell type. Blue indicates testis or testis-derived cells, orange indicates blood or blood-derived cells, and
gray indicates all other tissues/cell types.
doi:10.1371/journal.pgen.0030181.g004
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Normally Methylated CpG Island PromotersFTMT, C12orf12, and DPPA5), slightly reduced methylation
was observed in DNMT1 partial knockout cells with almost no
changes in DNMT3b knockout cells. By contrast, the
methylation level of SOHLH2 was signiﬁcantly decreased in
DNMT1 knockout cells (from 88% to 26%), and slightly less
but still signiﬁcantly reduced in DNMT3b knockout cells (to
40%). Consistent with methylation results, expression of all
genes analyzed was observed in DKO cells, and expression of
SOHLH2 gene was also found in DNMT1 knockout cells
(Figure 8B).
Discussion
During development, a small but signiﬁcant number of
CGIs become methylated and stably silenced [27]. This
process of developmentally programmed CGI methylation
has been best characterized in genomic imprinting and X
chromosome inactivation. Here, using a restriction enzyme–
based MCAM approach, we found that non-CGI and sparse-
CGI promoters were more susceptible to methylation than
dense-CGI promoters, in agreement with a very recent report
using an antibody approach to compare methylation proﬁles
between three classes of promoters [28]. Although most
dense-CGI promoters remain free of methylation, we found a
small exceptional class of such promoters (4.0%) that become
methylated in normal somatic tissues and are not associated
with X-chromosome or imprinted genes. By detailed charac-
terization of a subset of such genes, we found dense promoter
CGI methylation and gene silencing in most normal somatic
tissues except germ-line cells. Using RT-PCR and data from
published microarray experiments, we conﬁrmed tissue-
speciﬁc silencing for this class of genes. Further, we showed
that inhibition of methylation reactivates expression in these
genes. Our results suggest that DNA methylation plays an
important role in silencing germ-cell speciﬁc genes in
somatic tissues. A previous analysis of methylation using
RLGS (restriction landmark genome scanning) identiﬁed 150
regions (including promoters, exons, and introns) as TDMs
(tissue-speciﬁc differentially methylated regions) in C57BL/6J
mice [29]. By comparing 14 of these mouse TDMs with the
human genome, six showed human homologs, and ﬁve had
conserved tissue-speciﬁc methylation and expression, being
preferentially expressed in testis [30]. Our results indicate
that this pattern affects a relatively large number of genes. On
the other hand, other studies failed to identify many dense
promoter CpG islands hypermethylated in normal tissues,
suggesting that the class of genes we describe here is unique.
It will be important to determine how methylation at these
promoter-associated CGIs is established and maintained. One
possibility is that methylation is instructed by local sequence
features. By comparing DNA sequence ﬂanking the center of
CGIs, we identiﬁed ﬁve sequence motifs signiﬁcantly enriched
in methylated promoter CGIs relative to the bulk of
unmethylated CGIs. Although these motifs do not match
known transcription factor binding sites, all of them have
signiﬁcant overlap with Alu, af a m i l yo fS I N E s( s h o r t
interspersed elements). Alu repeats are rich in CpG dinucleo-
tides and are common targets for DNA methylation. About
one-third of methylated CpGs in the genome are located
within Alu repeats. Alu repeats have been proposed as
methylation centers for neighboring genes [31] and we
hypothesize that Alu-related cis-regulatory elements may play
a role in establishment and/or maintenance of tissue-speciﬁc
methylation. Experimental approaches such as transfection
and transgenic studies will be needed to test this model.
Interestingly, while Alu repeats are almost completely
methylated in most tissues, some, particularly young Alu
repeats, are almost completely unmethylated in germ line
cells [32,33], similar to the genes described here. It remains
unclear why tissue-speciﬁc gene silencing by DNA methyl-
ation is relatively rare, since many genes showing tissue-
speciﬁc expression are not methylated. What is most excep-
tional about the genes we describe here is their restricted
expression in germ cells. Considering that testis is an
immune-privileged site, it is possible that some of these
genes, if expressed in somatic tissues, could trigger auto-
immune phenomena, justifying the need for a strong
mechanism to maintain silencing. In this respect, it is also
interesting that we observed hypomethylation of these genes
in several cancers. Although the causes and biological effects
of cancer-linked hypomethylation remain unclear, such
hypomethylation can lead to gene expression that induces
an immune response [34,35]. The patterns of methylation and
Figure 5. Five Motifs Significantly Enriched in Genes with Methylated CGIs
The motifs are represented as sequence logos. The frequency of occurrence was calculated by the number of genes found to match the motif in each
group/total number of genes in each group. p-Value (f) was calculated from Fisher exact test to test if the motif matches are significantly enriched in the
methylated group compared to unmethylated group. p-Value (Alu) was calculated by using MAST to match the motif to Alu consensus sequence.
doi:10.1371/journal.pgen.0030181.g005
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that some may well be cancer-testis antigens.
In summary, we have identiﬁed a group of non-X–linked
bona ﬁde promoter CpG islands that are densely methylated
in normal somatic tissues, escape methylation in germ line
cells, and for which DNA methylation is a primary mechanism
of tissue-speciﬁc gene silencing.
Materials and Methods
Tissue and cell line samples. Normal tissue samples were obtained
from one of the following sources: normal peripheral blood samples
from eight healthy donors (three females and ﬁve males); 12 normal
colon mucosa (ﬁve females and seven males), and three normal liver
samples (all males) from the MDACC tissue bank; normal brain,
breast, placenta, and testis tissues were purchased from BioChain
Institute (Hayward, CA); the sperm sample was obtained from a
healthy donor and human primary cells were obtained from Cambrex
BioScience (East Rutherford, NJ) and American Type Culture
Collection (ATCC, Manassas, VA). Tumor samples examined in the
present study constitute over 60 cell lines that cover 13 major tumor
types (bladder, breast, brain, colon, liver, lung, ovary, prostate,
kidney, skin, teratocarcinoma, leukemia, and melanoma) from ATCC.
Genomic DNA was extracted using a standard phenol–chloroform
method. DNA from the colon cancer cell line HCT116 with DNMT1
knockout, DNMT3b knockout and double knockout (DKO) were
kindly provided by Dr. Bert Vogelstein at the Johns Hopkins Kimmel
Cancer Center [25,26].
Fully methylated DNA was prepared by treating genomic DNA
with M.SssI methylase (New England Biolabs, Beverly, MA). Brieﬂy, 5
lg DNA was incubated at 37 8C in 300 ll containing 20 U of SssI
methylase, 320 lM S-adenosylmethionine (SAM, New England
Biolabs), and 13 NEB buffer 2 (New England Biolabs). During the
incubation, same amounts of SssI methylase and SAM were added one
more time to ensure the complete reaction. To verify complete
methylation, we performed bisulﬁte pyrosequencing analysis of seven
randomly selected genes that were completely unmethylated before
treatment, and found dense methylation at all CpG sites analyzed (41
CpG sties in total) after treatment (Table S2).
Patient samples. Primary colon cancer samples from ten colorectal
cancer patients and bone marrow samples from ten MDS patients
were collected at the Johns Hopkins Hospital and M. D. Anderson
Cancer Center in accordance with institutional policies. All patients
provided written informed consent. Tumors were selected solely on
the basis of availability.
MCAM. Methylated CpG island ampliﬁcation from fully methy-
lated DNA and normal peripheral blood was performed as described
[15]. A detailed protocol can be found in the document titled
Methylated CpG Island Ampliﬁcation (in the ‘‘Protocols’’ section; see
at http://rd.plos.org/10.1371_journal.pgen.0030181_01). Brieﬂy, 5 lg
of genomic DNA was digested with 100 U of methylation-sensitive
restriction endonuclease SmaI (New England Biolabs) for 16 h at 20
8C, which cuts unmethylated DNA and leaves blunt ends (CCC/GGG).
Subsequently, the DNA was digested with 20 U of methylation-
insensitive restriction endonuclease XmaI for 9 h at 37 8C, which
leaves sticky ends (C/CCGGG). Adaptors were ligated to the sticky
ends. The adaptors were prepared by incubation of the oligonucleo-
tide RMCA12 (59-CCGGGCAGAAAG-39)a n dR M C A 2 4( 5 9-
CCACCGCCATCCGAGCCTTTCTGC-39)a t6 58C for 2 min, followed
by cooling to room temperature for 30–60 min. 500 ng of digested
DNA was ligated to 5 nmol of adaptor using T4 DNA ligase
(Invitrogen, Carlsbad, CA). The PCR ampliﬁcation of sequences
ﬂanked by adaptors was performed in a 100 ll reaction mixture
comprising 67 mM Tris-HCl (pH 8.8), 4 mM MgCl2,1 6m M
NH4(SO4)2,1 0m Mb-mercaptoethanol, 0.1 mg/ml bovine serum
albumin, 5% DMSO, 300 lM dNTP mix, 100 pmol of RMCA24
primer, and 15 units of Taq polymerase (New England Biolabs). The
thermocycling conditions were 5 min at 72 8C to ﬁll in the
Figure 6. DNA Methylation and Gene Expression Analyses in Cancers
(A) Profiles of promoter methylation of seven identified genes and global
methylation in cancer cell lines by bisulfite pyrosequencing.
(B) Gene expression analysis in selected cancer cell lines.
(C) Methylation profiles in primary tumors.
doi:10.1371/journal.pgen.0030181.g006
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min; this was then followed by 25 cycles of 1 min at 95 8C and 3 min at
77 8C, with a ﬁnal extension of 10 min at 72 8C.
Human promoter arrays were purchased from Agilent Technolo-
gies (Agilent, Santa Clara, CA). Microarray protocols, including
labeling, hybridization and post-hybridization washing procedures,
can be found at http://www.agilent.com/. Brieﬂy, MCA products were
labeled with Cy5 (red) for fully methylated DNA or Cy3 (green) for
PBLs using a random primed Klenow polymerase reaction (Invitro-
gen’s BioPrime Array CGH Genomic Labeling Kit) at 37 8C for 3 h.
Labeled samples were then hybridized to arrays in the presence of
human Cot-1 DNA for 40 h at 65 8C. After washing, arrays were
scanned on an Agilent scanner and analyzed using Agilent Feature
Extraction software at M.D. Anderson Microarray Core Facility.
Computational hybridization analysis. We built a database to
simulate the performance of MCAM in detecting hypermethylated
CpG islands using the SmaI/XmaI isoschizomers. Human genome
sequences were downloaded from the UCSC Genome Database
(http://genome.ucsc.edu/; version hg17, May 2004). The SmaI/XmaI
site ‘‘CCCGGG’’ was searched along each chromosome in a case
insensitive fashion. Fragments between two SmaI/XmaI sites were
extracted. If the fragment length was between 20 b and 10 kb, the
fragment was saved in FASTA format with the ﬁrst line indicating
chromosome number, the starting point of the fragment along
chromosome (counting from CCCGGG), and the length of the
fragment (including starting and ending CCCGGG).
Annotation of CGIs and repetitive regions. CGIs were classiﬁed
into three classes: dense-CGIs contain a 500 bp area with GC content
above 55% and CpG ratio above 0.65; non-CGIs do not contain a 200
bp area with GC content above 50% and CpG ratio above 0.60; and
sparse-CGIs are neither dense-CGI nor non-CGI, thus contain CGIs
that are either small or have moderate CpG richness. GC content was
calculated based on the number of C and G nucleotides within the
sequences analyzed. We used the formula cited in Gardiner-Garden et
al. [36] to calculate the CpG ratio (Obs/Exp CpG): (Number of CpG3
total number of nucleotides in the sequences analyzed) 4 (number of
C 3 number of G). Repetitive regions were masked in the genome
downloaded from UCSC genome database using RepeatMasker/
RepBase (versions: RepBase Update 9.11, RM database version
20050112). The databases for SmaI/XmaI fragments were in FASTA
format with annotations for (1) chromosome, (2) start point of the
fragment along the chromosome, (3) length of the fragment, (4) status
of CGI in the starting site, (5) status of CGI in the ending site, (6) if the
starting site was within repetitive region, and (7) if the ending site was
within repetitive region.
Probe sequences were downloaded from the Agilent website at
http://www.agilent.com/. Each probe was BLASTed against all sequen-
ces in the SmaI/XmaI database using BLAST v2.2.8 downloaded from
NCBI (http://www.genebee.msu.su/blast_new/blastform.
php?program¼blastn). Probes with multiple BLAT hits were excluded
from further study. Probes residing in SmaI/XmaI fragments were
identiﬁed with the annotation for fragment length, status of CGI, and
repetitive sequences.
Microarray analysis. We used probes located outside of SmaI/XmaI
fragments (length up to 10 kb) for normalization and background
calculation. The signal intensity for the probes within the SmaI/XmaI
fragments was adjusted for background and analyzed for the ratio
between Cy3 and Cy5 signals. All data analysis (sensitivity and
reproducibility, correlation between methylation level and chromo-
some location, CGI, and repetitive sequences) were carried out in
Excel (Microsoft). The resulting data sets are accessible in Table S1.
We used the following criteria to select hypermethylated probes in
PBL (Cy3) relative to fully methylated DNA (Cy5): signal intensity of
Cy3 . 3 3background and ratio of Cy3/Cy5   1.5 3 background. We
performed bisulﬁte pyrosequencing on 38 randomly selected genes
Figure 7. Gene Expression and DNA Methylation Changes after
Treatment with DAC or TSA
(A) Examples of RT-PCR results. The cell name and tissue type are
indicated on the top. The name of each gene amplified is indicated on
the left of each column. Cells were treated with 1 lM DAC, 5 lM DAC,
200 nM TSA, a combination of 1 lM DAC and 200 nM TSA (DACþTSA) or
no drug as a control (Ctr).
(B) DNA methylation analysis in each promoter region after treatment.
Reduced methylation level was detected after DAC and the combination
of DAC and TSA treatment. By contrast, TSA did not affect the
methylation of any gene.
doi:10.1371/journal.pgen.0030181.g007
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criteria most accurately identiﬁed hypermethylated loci.
Cell lines and culture conditions. Six cancer cell lines from ﬁve
tumor types: 786–0 (renal), K562 (leukemia), HCT116 (colon), UC13
(bladder), MCF7, and HTB126 (breast) were purchased from ATCC.
786–0, K562, and MCF7 were grown in RPMI 1640 containing 10%
fetal bovine serum. HCT116 and HTB126 were grown in high-glucose
Dulbecco’s modiﬁed Eagle’s medium containing 10% fetal bovine
serum. UC13 was grown in MEM Earle’s Salts plus NEAA and 10%
fetal bovine serum. Media were purchased from Invitrogen. Two
human primary cells, PrEC (prostate) and HMEC (breast), were
obtained from Cambrex BioScience and cultured in the media
according to the supplier’s instructions up to a maximum of ﬁve
passages. PrECs were grown in prostate epithelial cell growth medium
(Clonetics PrEGM bullet kit) containing 0.4% bovine pituitary
extract, 5 lg/ml hydrocortisone, 0.5 ng/ml recombinant human
epithelial growth factor, 0.5 lg/ml epinephrine, 10 lg/ml transferrin,
5 lg/ml insulin, 0.1 ng/ml retinoic acid, and 6.5 ng/ml triiodothyr-
onine. HMEC cells were grown in mammary epithelial cell basal
medium (Clonetics MEMG bullet kit) containing 0.4% bovine
pituitary extract, 5 lg/ml hydrocortisone, 0.5 ng/ml recombinant
human epithelial growth factor, and 5 lg/ml insulin.
5-Aza-29-deoxycytidine (DAC) and trichostatin A (TSA) treatment
of cells. Cells were split 12–24 h before treatment. Cells were then
given one of the following treatments. (1) DAC (1 or 5 lM; Sigma,
MO) or phosphate-buffered saline for 72 h. Medium containing DAC
or phosphate-buffered saline was changed every 24 h. (2) TSA (200
nM; MP Biomedicals, OH) or an identical volume of ethanol for 24 h.
(3) DAC (1 lM) for 48 h followed by DAC (1 lM) and TSA (200 nM) for
an additional 24 h. The timing and sequencing of DAC and/or TSA
were based on our preliminary studies as well as published studies
[37].
Bisulﬁte-pyrosequencing for promoter and global DNA methyl-
ation analysis. Bisulﬁte treatment was performed as reported
previously [38]. Brieﬂy, 2 lg of genomic DNA was denatured with 2
M NaOH for 10 min, followed by incubation with 3 M sodium
bisulﬁte (pH 5.0) for 16 h at 50 8C. After treatment, DNA was puriﬁed
by using a Wizard Miniprep Column (Promega, Madison, WI),
precipitated with ethanol, and resuspended in 30 ll of distilled
water. 2 ll of the aliquot were used as template for PCR.
We used a quantitative bisulﬁte pyrosequencing method for all
DNA methylation analyses [39,40]. Global DNA methylation was
measured by the LINE1 methylation as previous report [41]. Primer
sequences and PCR conditions for bisulﬁte pyrosequencing assays are
summarized in Table S3. The methylation levels at different C sites
measured by pyrosequencing were averaged to represent the degree
of methylation in each sample for each gene. For each assay, set-up
included positive controls (samples after SssI treatment) and negative
controls (samples after whole genomic ampliﬁcation), mixed experi-
ments to rule out bias, and repeated experiments to assess
reproducibility. Optimizing annealing temperature of PCR was used
to overcome PCR bias as reported [40].
Bisulﬁte sequencing. For selected genes, bisulﬁte sequencing
(performed at the M. D. Anderson Core Sequencing Facility) of
cloned PCR products was used to conﬁrm methylation of CpG sites
within the CGI promoters. For this analysis, we cloned the PCR
products into the TA vector pCR2.1 (Invitrogen) and extracted
plasmid DNA from the resulting clones with the use of a QIAprep
Spin Miniprep kit (Qiagen, Valencia, CA).
RNA extraction and RT-PCR. A panel of RNA from 20 different
normal human tissues was obtained from BD Biosciences (multiple
tissue cDNA panels) that comprises cerebellum, whole brain, fetal
brain, fetal liver, heart, kidney, lung, placenta, prostate, salivary
gland, skeletal muscle, spleen, testis, thymus, trachea, uterus, colon,
small intestine, spinal cord, and stomach. RNA from normal
peripheral blood, sperm and cell lines was prepared by using TRIzol
reagents (Invitrogen).
Total RNA (2 lg) was used as a template to generate comple-
mentary DNA (cDNA) by random hexamers and M-MuLV reverse
transcriptase (Roche, Indianapolis, IN). Reverse-transcription sam-
ples without reverse transcriptase also were included as negative
controls. One-thirtieth of the cDNA product was used to amplify a
306-bp product of glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) gene as an RNA quality control and one-tenth of the
cDNA was used to amplify individual genes. The primer sequences
and exons analyzed for RT-PCR were listed in Table S4. PCR
conditions were as follows: the reaction volume was 50 ll; initial
denaturation was 15 min at 95 8C, followed by 25 cycles (for GAPDH)
or 35 cycles (for other genes) of 30 s at 95 8C, 30 s at 55 8C, and 30 s at
72 8C, with a ﬁnal extension at 72 8C for 10 min. PCR products were
visualized on 6% polyacrylamide gels stained with ethidium bromide.
Bioinformatic analysis. We used GOstat [18] (http://gostat.wehi.edu.
au/) from Gene Ontology Tools (http://www.geneontology.org/GO.
tools.shtml) for gene ontology analysis and determined the statistical
signiﬁcance of the overlap with each gene ontology (GO) category
using the Fisher exact test. The default multiple testing correction is
the Benjamini-Hochberg procedure [42] to control false discovery
rate. For gene expression pattern analysis, we downloaded the
original proﬁles from GNF expression database (http://expression.gnf.
org/) using probes corresponding to genes identiﬁed as dense-CGI
promoters methylated in normal blood. From this database, we were
able to obtain gene expression data for 127 genes in a panel of 66
normal tissues/cells. To assign equal weight for expression of each
gene, we substituted all raw expression values in each data set by their
respective Z-scores, and the Z-score was calculated by (X l)/r, where
X stands for expression data of each gene in each sample; l stands for
mean of expression of each gene among all samples; and r stands for
standard deviation. To analyze expression for all genes, each tissue/
cell was assigned a score by the sum of Z-scores for all genes.
For sequence comparison analyses, we identiﬁed two groups of
autosomal genes with dense-CGI promoters based on MCAM results:
the methylated group, containing 138 genes with signal intensity of
PBLs relative to fully methylated DNA greater than 1.5; and the
unmethylated group, containing 2,125 genes with signal intensity of
PBL relative to fully methylated DNA less than 0.1. The general
features of CGIs analyzed in this study include CGI length, GC
content, and the ratio of observed to expected CpG frequency.
Statistical differences were analyzed by unpaired two-tailed t test.
Motif analysis was performed as previously reported [43,44]. We
generated two sets of sequence databases by extracting 2 kb genomic
segments (from the CGI center) for methylated and unmethylated
CGIs. Using each dataset as input into the MEME algorithm (http://
Figure 8. Methylation and Gene Expression Analysis in DNMT Knock-Out Cells
(A) DNA methylation analyzed by bisulfite-pyrosequencing in DNA methyltransferase 1 and 3b double knockout (DKO), DNMT1 partial knockout
(DNMT1 KO), DNMT3b knockout (DNMT3b KO), and parental HCT116 cells.
(B) Gene expression by RT-PCR in HCT116 with and without DNMT knockout.
doi:10.1371/journal.pgen.0030181.g008
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Normally Methylated CpG Island Promotersmeme.sdsc.edu/meme/intro.html) [19], we obtained the top 20 ‘‘best
ﬁt’’ motifs for both the methylated and unmethylated groups
(minLen ¼ 6, maxLen ¼ 50, with a position-speciﬁc goodness-of-ﬁt
p-value less than 10
 6 after Bonferroni-correction for multiple
testing). The 20 top motifs from each group were then individually
aligned to the entire two datasets with MAST (http://meme.sdsc.edu/
meme/intro.html) [20] to determine the number of occurrences of
each motif in methylated and unmethylated promoters. The Fisher
exact test was used to compare the frequency of each motif between
the two groups. We used TRANSFAC (http://www.gene-regulation.
com/cgi-bin/pub/databases/transfac/) to search for matches between
motifs with known transcription factor binding site. To evaluate if
the overlap between motifs and Alu consensus sequence is signiﬁ-
cantly greater than expected by chance, we used MAST to search for
matches and determine p-values.
Supporting Information
Figure S1. Outline of MCAM Method
(A) Schematic diagram of MCAM. A hypothetical fragment of
genomic DNA is represented by a solid box, with seven SmaI sites
(lollipops). Methylated SmaI sites are indicated by ﬁlled lollipops.
Fragments A, B, and C are CpG islands with two closely spaced (, 1
kb) SmaI sites. CpG island A is methylated in both samples, while B
and C are differentially methylated. Unmethylated SmaI sites are
eliminated by digestion with SmaI (which does not cut when its
recognition sequence, CCCGGG, contains a methylated CpG); SmaI
cleavage leaves blunt ends. The DNA is then digested with the
methylation-insensitive SmaI isoschizomer XmaI, which cleaves
methylated CCCGGG sites, leaving CCGG overhangs (sticky ends).
Adaptors are ligated to these sticky ends, and PCR is performed to
amplify the methylated sequences. The amplicons are labeled by Cy3
(green) for sample 1 and Cy5 (red) for sample 2. After hybridization
and scanning, hypermethylated fragments in sample 1 result in green
signal, hypermethylated fragments in sample 2 result red signal, and
equally methylated fragments result in a yellow signal.
(B) Representative results of MCA. 1.5% agarose gel images of MCA
amplicons from normal peripheral blood leukocytes (PBL) (sample 1)
and fully methylated DNA (sample 2).
(C) Example of microarray scanned image. Differential DNA
methylation was compared between fully methylated DNA (Cy5)
and normal PBL (Cy3).
Found at doi:10.1371/journal.pgen.0030181.sg001 (1.6 MB TIF).
Figure S2. Sensitivity and Reproducibility of MCAM
(A) Signal intensity of fully methylated DNA (Cy5) for probes located
within 10 kb of SmaI/XmaI fragments. Increased signal intensity was
found in 87.1% of probes located within 1 kb of the fragments.
(B) Scatter plot analysis of signal intensity (log scale) between fully
methylated DNA (y-axis) and normal PBL from a female donor (x-
axis) from MCAM. Red indicates probe methylated in fully
methylated DNA only and yellow indicates probe methylated in both
samples.
(C) Reproducibility of MCAM. Signal intensity of each probe (log
scale) from the same sample (PBL) but processed at two different
times.
Found at doi:10.1371/journal.pgen.0030181.sg002 (1.0 MB TIF).
Figure S3. Correlation between MCAM and Bisulﬁte-Pyrosequencing
for 38 Genes
All genes showed higher signal intensity in PBLs (A), and genes with
dense methylation showed a signiﬁcantly higher ratio relative to fully
methylated DNA (B).
Found at doi:10.1371/journal.pgen.0030181.sg003 (743 KB TIF).
Figure S4. Chromosomal Distribution of Methylated CGI Promoters
Identiﬁed from Normal Female Blood
Chromosomes number is indicated on the x-axis. Each bar represents
the number of genes methylated per chromosome. Black vertical bars
indicate gene promoters associated with dense-CGI, gray vertical bars
indicate gene promoters associated with sparse-CGI and white
vertical bars indicate gene promoters associated with non-CGI.
Found at doi:10.1371/journal.pgen.0030181.sg004 (875 KB TIF).
Figure S5. INSL6 Promoter Methylation Changes in HCT116 after
DAC or TSA Treatment
The degree of methylation (y-axis) at 17 single CpGs sites (x-axis) was
measured by quantitative bisulﬁte-pyrosequencing. Reduced methyl-
ation was found in cells after DAC or combination of DAC with TSA
at all C sites analyzed, in contrast, TSA alone has no effect on
methylation.
Found at doi:10.1371/journal.pgen.0030181.sg005 (703 KB TIF).
Table S1. List of Methylated Genes in PBLs Identiﬁed by MCAM
Found at doi:10.1371/journal.pgen.0030181.st001 (48 KB PDF).
Table S2. Validation of SssI Treatment by Methylation Analysis of 41
CpG Sites
Found at doi:10.1371/journal.pgen.0030181.st002 (7 KB PDF).
Table S3. Primer Sequences and PCR Conditions for DNA Methyl-
ation Analysis
Found at doi:10.1371/journal.pgen.0030181.st003 (9 KB PDF).
Table S4. Primer Sequences and PCR Conditions for RT-PCR
Analysis
Found at doi:10.1371/journal.pgen.0030181.st004 (7 KB PDF).
Accession Numbers
The National Center for Biotechnology Information (NCBI) (http://
www.ncbi.nlm.nih.gov) accession numbers for the genes studied in
this paper are shown in Tables 1 and S1. All microarray datasets in
this paper are available at Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo/) under the accession number GSE8810.
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